Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rare Primary Central Nervous System Tumors in Adults: An Overview.
Franceschi E, Frappaz D, Rudà R, Hau P, Preusser M, Houillier C, Lombardi G, Asioli S, Dehais C, Bielle F, Di Nunno V, van den Bent M, Brandes AA, Idbaih A; EURACAN Domain 10. Franceschi E, et al. Among authors: lombardi g. Front Oncol. 2020 Jun 26;10:996. doi: 10.3389/fonc.2020.00996. eCollection 2020. Front Oncol. 2020. PMID: 32676456 Free PMC article. Review.
Gliomas.
Lombardi G, Della Puppa A, Di Stefano AL, Pace A, Rudà R, Tabouret E, Zagonel V. Lombardi G, et al. Biomed Res Int. 2014;2014:470523. doi: 10.1155/2014/470523. Epub 2014 Aug 26. Biomed Res Int. 2014. PMID: 25243142 Free PMC article. No abstract available.
Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology).
Lombardi G, Pace A, Pasqualetti F, Rizzato S, Faedi M, Anghileri E, Nicolotto E, Bazzoli E, Bellu L, Villani V, Fabi A, Ferrazza P, Gurrieri L, Dall'Agata M, Eoli M, Della Puppa A, Pambuku A, D'Avella D, Berti F, Rudà R, Zagonel V. Lombardi G, et al. J Neurooncol. 2015 Nov;125(2):359-67. doi: 10.1007/s11060-015-1923-x. Epub 2015 Sep 30. J Neurooncol. 2015. PMID: 26423801
Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Mazza E, Brandes A, Zanon S, Eoli M, Lombardi G, Faedi M, Franceschi E, Reni M. Mazza E, et al. Among authors: lombardi g. Cancer Chemother Pharmacol. 2016 Jan;77(1):115-20. doi: 10.1007/s00280-015-2927-0. Epub 2015 Dec 11. Cancer Chemother Pharmacol. 2016. PMID: 26659583 Clinical Trial.
AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma.
Brandes AA, Finocchiaro G, Zagonel V, Reni M, Caserta C, Fabi A, Clavarezza M, Maiello E, Eoli M, Lombardi G, Monteforte M, Proietti E, Agati R, Eusebi V, Franceschi E. Brandes AA, et al. Among authors: lombardi g. Neuro Oncol. 2016 Sep;18(9):1304-12. doi: 10.1093/neuonc/now035. Epub 2016 Mar 6. Neuro Oncol. 2016. PMID: 26951379 Free PMC article. Clinical Trial.
Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study.
Brandes AA, Finocchiaro G, Zagonel V, Reni M, Fabi A, Caserta C, Tosoni A, Eoli M, Lombardi G, Clavarezza M, Paccapelo A, Bartolini S, Cirillo L, Agati R, Franceschi E. Brandes AA, et al. Among authors: lombardi g. Oncotarget. 2017 Feb 25;8(33):55575-55581. doi: 10.18632/oncotarget.15735. eCollection 2017 Aug 15. Oncotarget. 2017. PMID: 28903444 Free PMC article.
Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-Oncology.
Pasqualetti F, Pace A, Gonnelli A, Villani V, Cantarella M, Delishaj D, Vivaldi C, Molinari A, Montrone S, Pellerino A, Franchino F, Baldaccini D, Lombardi G, Lolli I, Catania F, Bazzoli E, Morganti R, Fabi A, Zagonel V, Bocci G, Fabrini MG, Rudà R, Soffietti R, Paiar F. Pasqualetti F, et al. Among authors: lombardi g. Am J Clin Oncol. 2018 Dec;41(12):1272-1275. doi: 10.1097/COC.0000000000000464. Am J Clin Oncol. 2018. PMID: 29782366
A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.
Brandes AA, Gil-Gil M, Saran F, Carpentier AF, Nowak AK, Mason W, Zagonel V, Dubois F, Finocchiaro G, Fountzilas G, Cernea DM, Chinot O, Anghel R, Ghiringhelli F, Beauchesne P, Lombardi G, Franceschi E, Makrutzki M, Mpofu C, Urban HJ, Pichler J. Brandes AA, et al. Among authors: lombardi g. Oncologist. 2019 Apr;24(4):521-528. doi: 10.1634/theoncologist.2018-0290. Epub 2018 Sep 28. Oncologist. 2019. PMID: 30266892 Free PMC article. Clinical Trial.
Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial.
Lombardi G, De Salvo GL, Brandes AA, Eoli M, Rudà R, Faedi M, Lolli I, Pace A, Daniele B, Pasqualetti F, Rizzato S, Bellu L, Pambuku A, Farina M, Magni G, Indraccolo S, Gardiman MP, Soffietti R, Zagonel V. Lombardi G, et al. Lancet Oncol. 2019 Jan;20(1):110-119. doi: 10.1016/S1470-2045(18)30675-2. Epub 2018 Dec 3. Lancet Oncol. 2019. PMID: 30522967 Clinical Trial.
Molecular Evolution of IDH Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study.
Draaisma K, Chatzipli A, Taphoorn M, Kerkhof M, Weyerbrock A, Sanson M, Hoeben A, Lukacova S, Lombardi G, Leenstra S, Hanse M, Fleischeuer R, Watts C, McAbee J, Angelopoulos N, Gorlia T, Golfinopoulos V, Kros JM, Verhaak RGW, Bours V, van den Bent MJ, McDermott U, Robe PA, French PJ. Draaisma K, et al. Among authors: lombardi g. J Clin Oncol. 2020 Jan 1;38(1):81-99. doi: 10.1200/JCO.19.00367. Epub 2019 Nov 19. J Clin Oncol. 2020. PMID: 31743054
2,107 results